These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
203 related articles for article (PubMed ID: 23730215)
1. Molecular and functional characterizations of the association and interactions between nucleophosmin-anaplastic lymphoma kinase and type I insulin-like growth factor receptor. Shi B; Vishwamitra D; Granda JG; Whitton T; Shi P; Amin HM Neoplasia; 2013 Jun; 15(6):669-83. PubMed ID: 23730215 [TBL] [Abstract][Full Text] [Related]
2. The transcription factors Ik-1 and MZF1 downregulate IGF-IR expression in NPM-ALK⁺ T-cell lymphoma. Vishwamitra D; Curry CV; Alkan S; Song YH; Gallick GE; Kaseb AO; Shi P; Amin HM Mol Cancer; 2015 Feb; 14():53. PubMed ID: 25884514 [TBL] [Abstract][Full Text] [Related]
3. Dual inhibition of IGF-IR and ALK as an effective strategy to eradicate NPM-ALK George B; George SK; Shi W; Haque A; Shi P; Eskandari G; Axelson M; Larsson O; Kaseb AO; Amin HM J Hematol Oncol; 2019 Jul; 12(1):80. PubMed ID: 31340850 [TBL] [Abstract][Full Text] [Related]
4. IGF-IR tyrosine kinase interacts with NPM-ALK oncogene to induce survival of T-cell ALK+ anaplastic large-cell lymphoma cells. Shi P; Lai R; Lin Q; Iqbal AS; Young LC; Kwak LW; Ford RJ; Amin HM Blood; 2009 Jul; 114(2):360-70. PubMed ID: 19423729 [TBL] [Abstract][Full Text] [Related]
5. PDGFR blockade is a rational and effective therapy for NPM-ALK-driven lymphomas. Laimer D; Dolznig H; Kollmann K; Vesely PW; Schlederer M; Merkel O; Schiefer AI; Hassler MR; Heider S; Amenitsch L; Thallinger C; Staber PB; Simonitsch-Klupp I; Artaker M; Lagger S; Turner SD; Pileri S; Piccaluga PP; Valent P; Messana K; Landra I; Weichhart T; Knapp S; Shehata M; Todaro M; Sexl V; Höfler G; Piva R; Medico E; Ruggeri BA; Cheng M; Eferl R; Egger G; Penninger JM; Jaeger U; Moriggl R; Inghirami G; Kenner L Nat Med; 2012 Nov; 18(11):1699-704. PubMed ID: 23064464 [TBL] [Abstract][Full Text] [Related]
6. The tyrosine 343 residue of nucleophosmin (NPM)-anaplastic lymphoma kinase (ALK) is important for its interaction with SHP1, a cytoplasmic tyrosine phosphatase with tumor suppressor functions. Hegazy SA; Wang P; Anand M; Ingham RJ; Gelebart P; Lai R J Biol Chem; 2010 Jun; 285(26):19813-20. PubMed ID: 20424160 [TBL] [Abstract][Full Text] [Related]
7. Nucleophosmin-anaplastic lymphoma kinase of large-cell anaplastic lymphoma is a constitutively active tyrosine kinase that utilizes phospholipase C-gamma to mediate its mitogenicity. Bai RY; Dieter P; Peschel C; Morris SW; Duyster J Mol Cell Biol; 1998 Dec; 18(12):6951-61. PubMed ID: 9819383 [TBL] [Abstract][Full Text] [Related]
8. TrkA is a binding partner of NPM-ALK that promotes the survival of ALK Shi W; George SK; George B; Curry CV; Murzabdillaeva A; Alkan S; Amin HM Mol Oncol; 2017 Sep; 11(9):1189-1207. PubMed ID: 28557340 [TBL] [Abstract][Full Text] [Related]
10. Involvement of Grb2 adaptor protein in nucleophosmin-anaplastic lymphoma kinase (NPM-ALK)-mediated signaling and anaplastic large cell lymphoma growth. Riera L; Lasorsa E; Ambrogio C; Surrenti N; Voena C; Chiarle R J Biol Chem; 2010 Aug; 285(34):26441-50. PubMed ID: 20554525 [TBL] [Abstract][Full Text] [Related]
11. Nucleophosmin-anaplastic lymphoma kinase: the ultimate oncogene and therapeutic target. Werner MT; Zhao C; Zhang Q; Wasik MA Blood; 2017 Feb; 129(7):823-831. PubMed ID: 27879258 [TBL] [Abstract][Full Text] [Related]
12. Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway. Marzec M; Kasprzycka M; Liu X; El-Salem M; Halasa K; Raghunath PN; Bucki R; Wlodarski P; Wasik MA Oncogene; 2007 Aug; 26(38):5606-14. PubMed ID: 17353907 [TBL] [Abstract][Full Text] [Related]
13. Activation of IGF-1R pathway and NPM-ALK G1269A mutation confer resistance to crizotinib treatment in NPM-ALK positive lymphoma. Li Y; Wang K; Song N; Hou K; Che X; Zhou Y; Liu Y; Zhang J Invest New Drugs; 2020 Jun; 38(3):599-609. PubMed ID: 31177400 [TBL] [Abstract][Full Text] [Related]
17. Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), a novel Hsp90-client tyrosine kinase: down-regulation of NPM-ALK expression and tyrosine phosphorylation in ALK(+) CD30(+) lymphoma cells by the Hsp90 antagonist 17-allylamino,17-demethoxygeldanamycin. Bonvini P; Gastaldi T; Falini B; Rosolen A Cancer Res; 2002 Mar; 62(5):1559-66. PubMed ID: 11888936 [TBL] [Abstract][Full Text] [Related]
18. Studies of phosphoproteomic changes induced by nucleophosmin-anaplastic lymphoma kinase (ALK) highlight deregulation of tumor necrosis factor (TNF)/Fas/TNF-related apoptosis-induced ligand signaling pathway in ALK-positive anaplastic large cell lymphoma. Wu F; Wang P; Zhang J; Young LC; Lai R; Li L Mol Cell Proteomics; 2010 Jul; 9(7):1616-32. PubMed ID: 20393185 [TBL] [Abstract][Full Text] [Related]
19. Oncogenic kinase NPM/ALK induces expression of HIF1α mRNA. Marzec M; Liu X; Wong W; Yang Y; Pasha T; Kantekure K; Zhang P; Woetmann A; Cheng M; Odum N; Wasik MA Oncogene; 2011 Mar; 30(11):1372-8. PubMed ID: 21102525 [TBL] [Abstract][Full Text] [Related]
20. Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1). Marzec M; Zhang Q; Goradia A; Raghunath PN; Liu X; Paessler M; Wang HY; Wysocka M; Cheng M; Ruggeri BA; Wasik MA Proc Natl Acad Sci U S A; 2008 Dec; 105(52):20852-7. PubMed ID: 19088198 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]